key: cord-0429515-dh8fzb2m
authors: Lin, Xian; Ke, Xianliang; Xia, Lin; Zhang, Tianying; Xiong, Hualong; Zhao, Binghai; Liu, Wen; Chen, Quanjiao; Tang, Chong
title: Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19
date: 2021-09-02
journal: bioRxiv
DOI: 10.1101/2021.09.01.458475
sha: 9f1542630a0e2e501af410944840cff038790f89
doc_id: 429515
cord_uid: dh8fzb2m

The COVID-19 pandemic is a global health disaster. Moreover, emerging mutated virus strains present an even greater challenge for existing vaccines and medications. One possible solution is to design drugs based on the properties of virus epigenome, which are more common among coronaviruses. Here, we reported an FDA-approved drug for myelodysplastic syndrome, azacytidine (5Aza), limited virus infection and protected mice against SARS-CoV-2. We demonstrated that this antiviral effect is related to 5Aza incorporation into viral RNA, which disrupt m5C RNA methylation modification profile. This work suggests that targeting viral epigenomes is a viable therapeutic strategy, potentially opening new pathways for treating COVID-19.

The COVID-19 pandemic is a global health disaster. Moreover, emerging 24 mutated virus strains present an even greater challenge for existing vaccines 25 and medications. One possible solution is to design drugs based on the 26 properties of virus epigenome, which are more common among coronaviruses. 27

Here, we reported an FDA-approved drug for myelodysplastic syndrome, 28 azacytidine (5Aza), limited virus infection and protected mice against 29 SARS-CoV-2. We demonstrated that this antiviral effect is related to 5Aza 30 incorporation into viral RNA, which disrupt m5C RNA methylation modification 31

profile. This work suggests that targeting viral epigenomes is a viable 32 therapeutic strategy, potentially opening new pathways for treating . properties of virus epigenome, which are more common among coronaviruses. 51

As an FDA-approved drug for myelodysplastic syndrome, 5Aza is a 52 structural analog of cytidine (Fig.S1 ). It exhibits antiviral effects against several 53 viruses. However, it is unknown whether this extends to SARS-CoV-2. 54

Here, we demonstrated that 5Aza shows potent antiviral activity in Vero E6 55 cells, with half-maximal inhibitory concentration (IC50) = 6.99 μM and selective 56 index (SI) = 20.41 (Fig.1a) . The viral titer in cell supernatants detection (Fig.1b ) 57 and indirect immunofluorescence assay (IFA) against viral N protein (Fig.1c ) 58 revealed 5Aza restricted SARS-CoV-2 infection in a dose-dependent manner. 59

Time-of-drug-addition assay (Fig.S2a) showed that 5Aza functioned after virus 60 entry (Fig.S2b, c, and d) . The virus replication is still 50% suppressed when 61 5Aza at 32 μM is added 24 hours after infection (Fig. S3) . 62

We then used 5Aza for in vivo antiviral evaluation in BALB/c mice infected 63 with a mouse-adapted SARS-CoV-2 (MA-SARS-CoV-2) that exhibits high 64 infectivity in mice. In clinical use, the recommended starting dose of 5Aza is 75 65 mg/m 2 (equals to ~2mg/kg) in treating MDS. Therefore, mice were intranasally 66 challenged with 2 × 10 3 plaque-forming units (PFU) of MA-SARS-CoV-2, 67 followed by intraperitoneal administration of 5Aza at 2 mg/kg body weight (equal to 6 mg/m 2 surface area) at 1 d post infection (dpi), once daily for seven 69 consecutive doses. As shown in Fig.1d , at 5 dpi, mice in 5Aza-treated group 70 started to recovery body weight, while mice body weight in saline-treated group 71

were still decreasing and 5/6 of mice lost more than 25% of body weight. 72

In accordance with this, 83.33% (5/6) of saline-treated animals became 73 moribund (defined as 25% loss of body mass) compared with 16.67% (1/6) in 74 5Aza-treated group. Besides, the viral RNA copy number and titers in the 75 lungs of 5Aza-treated mice also showed a significant decrease (Fig.1f) . 76

Moreover, histological examination revealed remarkable amelioration of lung 77 damage at 4 dpi in the 5Aza group (Fig.S4c ). In contrast, the saline group 78 exhibited massive alveolar space mononuclear cell infiltration, moderately 79 severe bronchiolar epithelial cell death, and intra-endothelium and 80 perivascular infiltration of pulmonary blood vessels (Fig.S4b) . The RNA-seq of 81 lungs also demonstrated that the 5Aza rescued most downregulated genes 82 with virus infection (Fig.S5 ), further demonstrated that 2 mg/kg 5Aza treatment 83 protected against SARS-CoV-2 attack. Based on the dose used in mice is 84 equivalent to that in treating MDS in humans, it would be encouraging to 85 extend to human COVID therapy. 86

As an RNA analog with OH-group on ribose 2′ carbon (2′ C) (Fig.S1a) , 87 5Aza could theoretically incorporate into RNAs. High-resolution mass 88 spectrometry analysis showed that RNA containing 5Aza increased ~40-fold with short-term 5Aza treatment (Fig.S6 ). We took advantage of 5Aza stability 90 in bisulfite treatment to develop a new method (5Aza-BSseq) that identifies the 91 location where 5Aza is incorporated (Fig.S7) . Notably, 5Aza-BSseq results 92 also suggested efficient azacytidine incorporation into viral RNA (Fig.1g) . 93

After deoxidized conversion to decitabine and incorporation into DNA, 5Aza 94 causes endogenous retrovirus (ERV) DNA hypomethylation, which activates 95 retroviral RNA transcription and triggers type I interferon response. In this study, 96 decitabine was five times less efficient than 5Aza in inhibiting viral replication 97 ( Fig.S8) . Additionally, 5Aza did not significantly increase ERV expression 98 (Fig.S9) . Therefore, 5Aza incorporation into RNA might be linked to its 99 inhibitory effects on viral replication. 100

We further explored the possible antiviral mechanism of 5Aza 101

incorporation into viral RNA. Previous research showed that 5Aza 102 incorporation enhanced lethal mutagenesis on influenza virus. However, we 103 found consistent mutations and comparable mutation rates in the viral RNA 104 propagated in 5Aza-treated or control cells (Supplementary Table 1) , 105 excluding the role of 5Aza-induced lethal mutagenesis in anti-SARS-CoV-2. 106

Considering that 5Aza sequesters tRNA methyltransferase to inhibit 107 cytosine-C5 methylation (m 5 C) in tRNA 1 (the reaction principle is exhibited in 108 Fig.S10 ), we further explored whether 5Aza incorporation affects viral RNA 109 methylation. We used nanopore direct RNA sequencing to avoid false-positive methylation sites caused by unconverted 5Aza, as assessed with bisulfite 111

sequencing. The nanopore m 5 C identification algorithm, trained by m 5 C control 112 data as well as many datasets, was used for data analysis. High-confidence 113 m 5 C sites in 5Aza-treated viral RNA decreased significantly by 40% (false 114 positive < 0.05) (Fig.1h) . We further validated these m 5 C sites using the 115 optimized RNA-BSseq and strict criteria ( Fig.S11 and S12). All m 5 C sites 116 identified through nanopore sequencing were also present in RNA-BSseq 117 (Fig.S13) . 118

The primary writers for m 5 C on mRNAs have been proposed to be NSUN2 119

and DNMT2, which are demonstrated to contribute to m5C methylation on 120

HIV-1 RNA and thus facilitate virus infection 2,3 . Here, we found that 121 overexpression of DNMT2 and NSUN2, significantly promoted the 122 SARS-CoV-2 replication (Fig.S14) , implying both of DNMT2 and NSUN2 are 123 responsible for the m 5 C methylation of SARS-CoV-2 RNA. The 124 immunoprecipitation (IP) assay showed that DNMT2 and NSUN2 could bind to 125 SARS-CoV-2 RNA (Fig. 1i) . Notably, DNMT2 IPed more RNAs in the presence 126 of 5Aza. As RNA methylation occurs, cytosine RNA methyltransferases 127 (m 5 C-RMTs) form a covalent thioester bond, connecting the cysteine residue 128 of its catalytic domain to the C6 position, thereby forming an m 5 C-RMT-RNA 129 adduct. Next, RMT transfers a methyl group from the cofactor S-adenosyl 130 methionine (SAM) to C5 of cytosine, followed by enzyme release from the adduct β-elimination. 5Aza is a suicide mechanism-based inhibitor of 132 m 5 C-RMTs 4 . RNAs containing 5Aza at the precise target site will sequester the 133 m 5 C-RMT by generating RNA-m 5 C-RMT adducts, which will result in the 134 decreased level of active endogenous enzymes 5 . Consistent with this theory, 135

we observed an obvious decreased DNMT2, rather than NSUN2 protein upon 136 5Aza treatment in SARS-CoV-2 infected cells (Fig. S15 ). It suggests that 137 DNMT2 is more likely the main enzyme for m 5 C RNA methylation in 138 SARS-CoV-2. Further investigations are underway to elucidate the relevance 139 of m 5 C methylation and SARS-CoV-2 infection to 5Aza treatment. 140

In summary, we demonstrated that 5Aza can incorporate into 141 SARS-CoV-2 RNA and disturb m 5 C RNA methylation modification, potentially 142 contributing to 5Aza's anti-SARS-CoV-2 activity. We repurposed 5Aza as a 143

promising candidate for combating COVID-19 and introduced the possibility of 144 targeting viral epigenomes as a novel antiviral strategy. intraperitoneally injected with 2 mg/kg 5Aza (SARS-CoV-2+5Aza group) or an 193 equivalent volume of sterile saline (SARS-CoV-2+saline and mock infection 194 groups), once daily for seven consecutive doses. d body weight was measured 195 daily for 7 d (n=6), mice with 25% body weight loss were considered moribund 196 and euthanized. Note: the remaining one mouse (body weight loss less than 197 25%) in SARS-CoV-2+saline group was not recorded at dpi 6 and 7. e the 198 survival rates of mice (n=6); mice with more than 25% of body weight loss in d 199

were considered moribund and euthanized. f at 4 dpi, three mice per group 200

were euthanized for detecting viral RNA copy and virus titer in the lungs. g The 201

pseudo m 5 C locations indicated incorporated azacytidine. Vero-E6 cells were 

Identification of direct targets and modified 149 bases of RNA cytosine methyltransferases

Cytosine methylation by DNMT2 facilitates stability and 152 survival of HIV-1 RNA in the host cell during infection

infected with 1 moi SARS-CoV-2 in the presence of 10 μM 5Aza or saline

After 12 h, total RNA was isolated and comparison of 5Aza-treated viral RNA 204 with the control using bisulfite sequencing was performed; the non-overlapping 205 points are pseudo m 5 C locations that indicate where 5Aza was incorporated

RNAs of cells infected with SARS-CoV-2 that treated with or without 5Aza 207 were subjected to Nanopore direct RNA sequencing. i Vero E6 cells transiently 208 overexpressing DNMT2, NSUN2, or GFP with a HA tag were infected with 0.2 209 moi SARS-CoV-2 for 20 h, in the presence of 16 μM 5Aza or not. Lysates were 210 prepared and split for incubation with mouse anti-HA antibody

RNA was analyzed by qRT-PCR using primer sets targeting viral S gene. The 212 level of viral RNA amplicon was determined as the percentage of input

lysate) (right); the expression of indicated protein and products of IP was 214 validated by western blot (left). Data are means ± SD analyzed using Student's 215 t test or One-way ANOVA

Log-rank test was used to 216 analyze the significance of survival differences